Published in Cancer Weekly, April 3rd, 2001
A. Eisbruch and colleagues examined the efficacy of gemcitabine at various doses, weighed against its dose-limiting toxicity in a Phase I trial. They measured levels of gemcitabine triphosphate (dFdCTP) in biopsied tumor cells before and during a standard seven-week course of radiation treatment for locally advanced head and neck cancer.
Gemcitabine was given weekly in doses starting at 300 mg/m2/week, and tapering off to 150...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.